1 **ARTICLE**
2 **A novel two-hit insomnia and inflammation rodent model of depressive-like behaviors**
3

4 **Running title:** A two-hit model of depression
5

6 Junhua Mei, M.D.[a]†; Xinhua Song, M.D.[b]†; Ying Wang, M.D.[c]†; Honggang Lyu, M.D.[a]†;
7 Guang Wang, M.D.[b]; Chao Chen, M.D.[b]; Honghan Zhang, M.D.[a]; Chao Wang, M.D.[a]; Xin-hui
8 Xie, M.D. & Ph.D.[a] *; Guohua Chen, M.D. & Ph.D.[b,d] *; Zhongchun Liu, M.D. & Ph.D.[a,e] *
9

[a] Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang Road,
Wuchang District, Wuhan 430060, China.

[b] Hubei University of Chinese Medicine, Wuhan, China.

[c] Department of Neurology, Traditional Chinese and Western Medicine Hospital of Wuhan,
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

[d] Department of Neurology, Wuhan First Hospital, No. 215 Zhongshan Road, Wuhan 430022,
China.

[e] Taikang center for life and medical sciences, Wuhan University, Wuhan, 430000, PR China.
18

19 † Co-first author
20

*Corresponding authors:

1. Zhongchun Liu.

Address: 1) Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang
Road, Wuchang District, Wuhan, Hubei, PR China. ZIP: 430060. Telephone: 86-
8804191181399. 2) Taikang center for life and medical sciences, Wuhan University, Wuhan,
PR China. ZIP: 430071.

E-mail: zcliu6@whu.edu.cn
28

29 2. Guohua Chen

30 Address: Department of Neurology, Wuhan First Hospital, No. 215 Zhongshan Road, Wuhan
31 430022, China.

32 E-mail: cghys2008@126.com
33

34 3. Xin-hui Xie

35 Address: Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang
36 Road, Wuchang District, Wuhan, Hubei, PR China. ZIP: 430060

37 E-mail: xxh.med@gmail.com; xin-hui.xie@whu.edu.cn

ABSTRACT

Background: Systemic inflammation and insomnia often co-occur in patients with depression. However, there is no suitable animal model to investigate the relationship between inflammation, sleep deprivation (SD), and depression.

Methods: To model interactions between insomnia, inflammation, and depression, we developed a novel "two-hit" rodent model of depressive-like behaviors using continuous SD followed by daily lipopolysaccharide (LPS) treatment. Control groups received SD, LPS, or sterile phosphate-buffered salinealone. The model's validity was assessed at the cellular and molecular levels, with fluoxetine rescue applied to confirm model validity.

Results: The model group demonstrated significant depressive-like behaviors that were rescued by fluoxetine treatment. Transcriptomic analysis revealed alterations in neuroinflammation and synaptic plasticity pathways within the hippocampus and prefrontal cortex (PFC) of model rats. Western blotting validated alterations in key protein markers related to both processes, and immunofluorescence confirmed microglia and astrocyte activation, indicative of neuroinflammation. Additionally, transmission electron microscopy and Golgi-Cox staining revealed reduced synapse and dendritic spine density in the model group. Fluoxetine treatment reversed these structural changes. Sixteen genes associated with neuroinflammation and synaptic function were validated in human genetic studies by transcriptome-wide association analysis.

Conclusion: This reliable two-hit model will be useful for investigating the roles of insomnia and inflammation in depression.

INTRODUCTION

Depression is extremely common and frequently recurs, and it is expected to be the leading disease in terms of global burden by 2030 [1]. Depression is a complex and clinically and biologically heterogeneous, with a multifactorial etiology [2]. Traditional hypotheses to explain depression, such as the neurotransmitter and receptor hypothesis, the hypothalamic-pituitary-adrenal axis hypothesis, and the neuroplasticity hypothesis, certainly provide insights into the etiology of depression. However, these hypotheses do not fully explain the underlying pathobiology nor do they completely explain the complex clinical phenotypes [3], and other mechanisms are now thought to contribute to the disease process. In this regard, and based on clinical observations, recent studies have focused on the roles played by insomnia and inflammation in depression [4-6].

The relationship between insomnia, inflammation, and depression is complex. Insomnia is commonly observed in individuals with depression [7], and insomnia may be a predictor of depression recurrence [8]. A meta-analysis of individuals with insomnia concluded that insomnia was associated with elevated systemic inflammatory markers [9]. Insomnia also activates multiple inflammatory pathways, such as the transcription of proinflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways and proinflammatory interleukin-6 (IL-6) [10, 11]. Similarly, there is a well-established relationship between inflammation and depression. Several meta-analyses have demonstrated that, even after accounting for confounding, inflammatory markers are significantly increased in patients with depressive disorders compared with healthy controls [12, 13]. Complementing these cross-sectional data, longitudinal cohort studies have also indicated that children with elevated serum IL-6 and C-reactive protein were at significantly increased risk of developing depressive disorders during adolescence [14].

Importantly, inflammation and insomnia often co-occur in patients with depression, and insomnia-related and inflammatory processes induced by infection and psychological stress elevate depression risk [15, 16]. Clinical studies provide further evidence of an association between inflammation and the severity of insomnia or depressive symptoms [6]. Moreover, mediation analyses of the large National Health and Nutrition Examination Survey (NHANES) community sample also revealed that increased inflammatory markers might mediate the association between insomnia and depression [5]. Hence, Irwin and Piber proposed a two-hit hypothesis of depression, in which insomnia and inflammation collaborate as "two hits" in a population especially vulnerable to developing depression [16]. Despite this abundance of clinical evidence and a plausible hypothesis, there is a conspicuous absence of animal models to rigorously investigate the underlying biological mechanisms. Therefore, here we propose a novel rodent model of depression-like symptoms based on the two-hit hypothesis.

Our model simulates insomnia and inflammation using sleep deprivation (SD) and lipopolysaccharide (LPS) treatment, respectively. We evaluate our model from the etiological, phenomenological, and therapeutic perspectives. The induction of depressive-like behaviors by combined insomnia and inflammation was confirmed through behavioral assessments. Transcriptomic analysis defined the molecular signaling effects of the two hits of SD and inflammation on the hippocampus and prefrontal cortex (PFC), with further confirmatory exploration of the underlying pathobiology with western blotting, immunofluorescence, transmission electron microscopy (TEM), and Golgi-Cox staining validating the transcriptional

patterns. Furthermore, we performed fluoxetine rescue experiments to assess the efficacy of fluoxetine in this model. Finally, we provide genetic evidence from human transcriptome-wide association analysis (TWAS) that supports the two-hit model and implicates neuroinflammation and synaptic dysfunction in depression pathology.

MATERIALS AND METHODS
The two-hit depressive-like model
Animals

All experiments were conducted on eight-week-old male Sprague Dawley rats purchased from Liaoning Changsheng Biotechnology Co., Ltd. (Liaoning, China, License Number: SCXK (Liao) 2020-0001). Rats were acclimatized to the new surroundings for seven days before commencing experiments. The Animal Ethics and Welfare Committee at Renmin Hospital of Wuhan University approved all experimental protocols (WDRM Dong (Fu), No. 20230603C).

Sleep deprivation

Chronic SD was conducted using an improved multi-platform water environment method [17]. Rats were housed each day in 75 x 50 x 36 cm^3 SD boxes containing 8 cm diameter, 8 cm high platforms spaced 15 cm apart, with water injected to 1 cm above the platforms. Rats underwent continuous SD for 18 days, with each day lasting 18 hours (15:00 – 09:00). The water temperature during SD was maintained at 25°C ± 2°C.

LPS treatment

LPS (O111:B4, Sigma-Aldrich, St. Louis, MO) was administered intraperitoneally (i.p.) in sterile phosphate buffered saline (PBS) at a dose of 0.8 mg/kg/day, calculated as a volume of 5.0 ml/kg.

Fluoxetine treatment

Fluoxetine (J20170022, Patheon, Bourgoin-Jallieu, France) was dissolved in drinking water and administered by oral gavage at a dose of 10 mg/kg/day in a volume of 2 mg/ml.

Model experiment

Forty-eight Sprague Dawley rats were acclimatized for seven days. Then, after the first behavioral assessment (sucrose preference test, SPT), rats were randomly assigned to four groups: control (CON, n = 12), LPS treatment (LPS, n = 12), sleep deprivation (SD, n = 12), and the model group (MOD, n = 12). Subsequent procedures are shown in **Fig. 1A**. The CON group was housed normally in cages and received a daily i.p. injection of 5.0 ml/kg sterile PBS solution from days 18 to 21. The LPS group was housed normally and received a daily i.p. injection of 0.8 mg/kg LPS solution from days 18 to 21. The SD group underwent 18 hours of SD daily from days 1 to 18, followed by a daily i.p. injection of 5.0 ml/kg sterile PBS solution from days 18 to 21. The MOD group underwent 18-hour SD daily from days 1 to 18, followed by a daily i.p. injection of 0.8 mg/kg LPS solution from days 18 to 21.

On the 21st day, a second set of behavioral assessments were conducted (the SPT and the forced swimming test (FST)) to evaluate depressive-like behaviors in each group. After the FST, each group was euthanized and hippocampal and PFC tissue excised.

Fluoxetine rescue experiment

The flowchart for the fluoxetine rescue experiment is shown in **Fig. 1D**. Following a seven-day acclimatization period, 36 rats were randomly assigned to two groups at a 1:2 ratio: the control group (CON, n = 12) and the model group (MOD, n = 24). Subsequent procedures were similar to those in the model experiment. On the 22nd day, after the second behavioral assessment, the model group was randomly divided into two subgroups: the physiological saline treatment group (SAL, n = 12) and the fluoxetine treatment group (FLX, n = 12).

Fluoxetine (10 mg/kg) was administered daily via gastric lavage to the fluoxetine group,

while the saline group received an equal volume of physiological saline daily. The control
group was maintained under normal cage conditions. The rats underwent the same 21-day
modeling as described in the model experiment. On the 42nd day, the third set of behavioral
assessments was conducted, including the SPT and FST, to evaluate depressive-like behaviors
in each group. Then, all rats were euthanized, and hippocampus and PFC tissue were excised.

Behavioral assessments

Details of the behavioral assessments (SPT, FST) are provided in **Supplemental File 1**.

Transcriptome analysis

Principal component analysis for comparative analysis

Principal component analysis (PCA) was performed to examine the differences between
samples [18].

Clustering and visualization of gene expression

The R package "*ClusterGVis*" was used to perform *k*-means clustering and to visualize
differences in gene expression profiles from the hippocampus and PFC between the different
groups (https://github.com/junjunlab/ClusterGVis).

Differentially-expressed genes (DEGs) and enrichment analysis

Differential expression analysis (DEA) was performed using the "*DESeq2*" package [19] in R
to identify DEGs between the experimental groups (MOD, LPS, and SD) and the control group.
Genes with an absolute fold change ≥ 1.2 and an adjusted *p*-value (adj. *p*-value) < 0.05 were
considered statistically significant DEGs. To further investigate molecular mechanisms in the
two-hit model, gene set enrichment analysis (GSEA) and Gene Ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) analyses were performed to explore signaling
pathways in both the hippocampus and PFC using the R package "*clusterProfiler*" [20]. Next,
as an exploratory analysis, Bayesian networks inferred from gene expression data based on
enrichment analysis results were visualized using the "*CBNplot*" package in R [21].

Validation of depression-related biological phenotypes

We used a battery of techniques to examine depression-related biological phenotypes in the
hippocampus and PFC related to the transcriptomic results. Fiji/ImageJ software was used to
analyze western blotting, immunofluorescence, TEM, and Golgi-Cox staining images. The
specific methods are detailed in **Supplemental File 1**.

Western blotting

Western blotting was used to confirm changes in expression of synaptic plasticity (PSD95,
SYN-1, SYP, and BDNF) and neuroinflammation (NLRP3, ASC) markers. The following
primary antibodies were used: PSD95 (ABclonal, Woburn, MA; A7889, 1:2000), SYN-1
(Proteintech, Rosemont, IL; 20258-1-AP, 1:4000), SYP (Cell Signaling Technology, Danvers,
MA; 5461T, 1:2000), BDNF (Abcam, Cambridge, UK; ab108319, 1:2000), NLRP3 (Abcam,
ab263899, 1:1000), ASC (ABclonal, A1170, 1:1000).

Immunofluorescence

Immunofluorescence was used to detect and visualize specific proteins or antigens in cells or
tissues. The immunofluorescence method is detailed in **Supplemental File 1**.

Transmission electron microscopy

TEM is a powerful technique used to visualize the ultrastructure of biological specimens at

near-atomic resolution. For accurate quantification, we differentiated synaptic structures according to the following criteria: both pre- and postsynaptic thickened structures and at least three vesicles within a 0.1 μm range on the presynaptic side. We quantified the number of synapses (measured in micrometers squared, μm^2), the area of readily released vesicle pools, and the dimensions of the postsynaptic densities to observe synaptic ultra-microstructures in the hippocampus [22].

Golgi-Cox staining

Golgi-Cox staining was used to visualize neurons and their dendritic trees in hippocampal tissue sections (**Supplemental File 1**). Dendrites on the secondary branches of neurons were selected, with the length of each dendritic segment exceeding 10 μm.

Transcriptome-wide association studies

To further validate whether DEGs from the two-hit model are also associated with human depression, we used the FUSION (http://gusevlab.org/projects/fusion/) framework to perform TWAS [23]. This method leverages tissue-specific expression quantitative loci (eQTL) information across multiple human tissues to identify putative causal genes for a phenotype. Here, we performed brain-specific tissue TWAS leveraging 13 brain tissues available from GTExV8 (https://gtexportal.org/home/aboutAdultGtex). The depression Genome-wide association study (GWAS) summary data was downloaded from the iPSYCH website (https://ipsych.dk/en/research/downloads). A false discovery rate (*FDR.p*) was applied in multiple testing.

RESULTS

Behavioral assessments

The model group displayed significant depressive-like behaviors (**Fig. 1B,C**). Compared to controls, model rats exhibited a significant decrease in SPT ($p < 0.01$) and a significant increase in immobility time in the FST ($p < 0.01$). The LPS group also displayed similar behavioral alterations. By contrast, the SD group did not show significant depressive-like behaviors.

In the fluoxetine rescue experiment, fluoxetine rescued these depressive-like behaviors induced by combined SD and LPS (**Fig. 1E,F**).

Hippocampus and PFC transcriptomes

PCA

PCA plots depicting the distribution of samples based on gene expression profiles in the hippocampus and PFC are shown in **Supplemental Fig. 1**.

Clustering and visualization of gene expression

Analysis of hippocampus and PFC transcriptomes identified eight distinct clusters (C1–C8) (**Fig. 2A,B**). In the hippocampus, cluster C5 was enriched for inflammation and immune pathways, including those involved in leukocyte and neutrophil migration and regulation of immune effector processes. Additionally, cluster C1 revealed contributions from cognition and learning or memory processes in the model group.

In the PFC, cluster C6 highlighted pathways associated with inflammatory and immune responses, while there was significant expression of synapse-related pathways, including vesicle-mediated transport in synapses, in cluster C3 (**Fig. 2B**).

DEGs and enrichment analysis

In the hippocampus, 238 DEGs were identified in the model group, of which 195 were upregulated and 133 were downregulated. GSEA analysis revealed significant enrichment of inflammatory and immune response pathways in the model group, including those related to leukocyte migration, immune activation, and cytokine-mediated signaling. Conversely, there was downregulation of synaptic pathways involved in postsynaptic density, asymmetric synapses, neuron-to-neuron synapses, GABAergic synapses, and regulation of synaptic plasticity in the model group (**Fig. 2C**).

In the PFC, 123 DEGs were identified in the model group, of which 64 were upregulated and 59 were downregulated. Similarly, GSEA analysis also showed significant activation of inflammatory and immune response pathways (**Fig. 2D**). Detailed DEA results are presented in **Supplemental Table 1**.

Over-representation analysis (ORA) of DEGs within the GO database yielded similar results. In the model group, upregulated DEGs in the hippocampus were significantly enriched for inflammatory and immune response pathways, while downregulated DEGs were enriched for synapse-related pathways (**Fig. 3A,C**). Additionally, to provide a deeper understanding of the underlying mechanisms behind these molecular pathways (**Fig. 3B, D, F, and H**), we explored Bayesian networks among these pathways. Detailed ORA results are presented in **Supplemental Table 2**.

Validation of depression-related biological phenotypes

Transcriptomic analysis suggested involvement of neuroinflammation and synaptic plasticity
in the model group. We therefore applied several methodologies to validate these alterations in
neuroinflammation and synaptic processes within the hippocampus and PFC.

Neuroinflammation
As shown in **Fig. 4,** in the hippocampus and PFC of model rats, there was significant
upregulation ($p < 0.05$) of inflammatory proteins such as NLRP3 and ASC compared with
control. Immunofluorescence analysis confirmed cellular-level changes, as evidenced by
increased GFAP$^+$ and IBA-1$^+$ cells, suggesting activation of astrocytes and microglia in the
dentate gyrus (DG), CA1, and CA3 regions of the hippocampus. Similar observations were
noted in the PFC.

In the fluoxetine rescue experiment, as expected, there was decreased expression of
NLRP3 and ASC in both the hippocampus and PFC in the fluoxetine group ($p < 0.05$), and
immunofluorescence analysis also revealed that fluoxetine rescued alterations in GFAP$^+$ and
IBA-1$^+$ cells (**Supplemental Fig. 5**).

Synaptic plasticity
As shown in **Fig. 5,** decreased expression of synapse-related proteins, including PSD95, SYN,
and SYP, was observed in the hippocampus and PFC of model rats ($p < 0.05$). Additionally,
BDNF expression was significantly downregulated ($p < 0.05$). Moreover, combined SD and
LPS treatment produced ultra-structural changes in synaptic structures. TEM revealed a
decrease in synapse numbers and the average size of synaptic vesicles of the readily releasable
pool (RRP), together with a reduction in the length and thickness of the postsynaptic density
(PSD) in the hippocampus. Golgi-Cox staining indicated a reduction in the number of dendritic
spines, which were shorter, narrower, and elongated.

In the fluoxetine rescue experiment, as expected, the fluoxetine group exhibited increased
protein expression of PSD95, SYN, SYP, and BDNF in the hippocampus ($p < 0.05$).
Furthermore, reversible alterations in synaptic ultra-structures and dendritic spine morphology
were observed within the fluoxetine group. However, no similar changes were observed in the
PFC (**Supplemental Fig. 6**).

Validation of depression-related DEGs based on TWAS
A central goal of this study was to validate DEGs identified in the two-hit model (model group)
using data derived from human genetics studies of brain tissues. Thirty-three genes overlapped
by intersecting DEGs with genes associated with depression in TWAS (Benjamini-Hochberg
correction $p < 0.05$), with 29 found in the hippocampus and four in the PFC (**Supplemental**
Table 3). By comparing Z-scores from TWAS with identified DEGs in transcriptomes analyses,
we observed consistent directional changes in expression for 16 genes (**Fig. 6**). Interestingly,
the significant TWAS gene set contained genes that regulate inflammatory and immune
responses, exemplified by *TLR9* and *C4A*, and those implicated in the modulation of
neurotransmitter release, like *CTTNBP2*. These findings are consistent with our experimental
observations, reinforce the two-hit model, and suggest a fundamental connection between
insomnia, inflammation, and depression.

DISCUSSION

In this study, based on the two-hit hypothesis [16], we devised a novel rodent model of depressive-like behaviors that used chronic SD to simulate insomnia and LPS treatment to simulate inflammation. The model was validated from the etiological, phenomenological, and therapeutic perspectives. Additionally, significant neuroinflammation and impaired synaptic plasticity were observed in the model group, which are consistent with observations in the clinical trials. Furthermore, validation of a subset of the DEGs identified in model rats through human TWAS analysis supports the two-hit model of depression development in humans.

A key criterion of efficacy of depression models is the assessment of depressive-like behaviors. We employed widely used depressive-like behavior tests to assess the models, with the results revealing that the model group exhibited typical depressive-like behaviors, consistent with findings from previous of depression models in rodents, such as unpredictable chronic mild stress, repeated restraint stress, and chronic social defeat stress [24-26].

Of note, after randomly assigning rats to different groups at baseline, we did not exclude any rats. Combined with the results of behavior tests, we believe that an advantage of this model is its high success rate and reliability. Moreover, fluoxetine rescued depressive-like behaviors, validating the model's efficiency from a therapeutic perspective. Thus, this novel rodent model fulfilled the three criteria for a depressive-like rodent model: (a) face validity (symptomatic homology), (b) etiological validity (similar causative factors), and (c) pharmacological validity (reversal of depressive symptoms by antidepressants) [27, 28].

A useful animal model of depression should not only demonstrate depressive-like behaviors but also recapitulate some main pathophysiological mechanisms responsible for depression. We therefore tested whether the model demonstrated some biological alterations seen in patients with depression. To obtain a preliminary picture of the model's impact on the brain, we selected two brain regions widely studied in depression research, the hippocampus and the PFC, and conducted transcriptomic analysis.

Our results revealed significant enrichment of DEGs in signaling pathways such as "inflammatory and immune response", "postsynaptic density", "dendritic spine", "regulation of synaptic plasticity", and "postsynapse organization" in the model group (**Fig. 2**). These pathways are crucial in neurotransmission and neurodevelopment and correspond to impairments found in human studies [29, 30]. To ensure the robustness of our transcriptomics findings, we further validated neuroinflammation and impaired synaptic plasticity at the cellular and protein levels.

Neuroinflammation is one of the most reproduced phenomena in patients with depression. A meta-analysis summarizing central inflammatory markers associated with patients with depression suggested significantly elevated levels of proinflammatory cytokines in the cerebrospinal fluid [31]. Our two previous clinical trials of blood astrocyte-derived extracellular vesicles also provided direct *in vivo* evidence of neuroinflammation in patients with depression [32, 33]. Western blotting validation also revealed upregulation of neuroinflammatory proteins, while immunofluorescence indicated activation of microglia and astrocytes, suggesting signs of neuroinflammation (**Fig. 4**). Similar results have also been observed in humans [34-36]. Based on the transcriptomic data and comprehensive validations, we believe that this model effectively simulates neuroinflammation-related mechanisms of depression.

Our results also illustrate the capacity of the two-hit model to replicate alterations in
synaptic plasticity, a frequently noted and highly replicable phenomenon in patients with
depression [37]. Transcriptomic analysis revealed impaired synaptic plasticity in both the
hippocampus and the PFC. This finding was further corroborated by western blotting, which
demonstrated a decrease in the expression of synaptic marker proteins. Additionally, TEM and
Golgi-Cox staining revealed a reduction in the number of synapses and dendritic spines,
respectively. Alterations in the density, number, and morphology of synapses and dendritic
spines have been observed in both depressive-like animal models and patients with depression
[38]. Imaging and postmortem studies have also suggested that synapse number and function
are decreased in patients with major depressive disorder [39]. Additionally, the number and
efficiency of synapses are also influenced by a variety of factors related to depression and other
mood disorders, such as neurotrophic factors and inflammatory cytokines [40, 41]. In summary,
both clinical and basic research highlight a pivotal role for synaptic plasticity in the
neurobiology of depression [37, 42, 43], further supported by our findings within the two-hit
model framework.

The pattern observed in the PFC was similar to that observed in the hippocampus, albeit
with subtle differences. Compared with controls, both the LPS and SD groups showed a
reduction in the expression of synaptic marker proteins within the PFC. This phenomenon is
thought to arise from a dominant cortical involvement induced by LPS treatment and SD, with
the hippocampus affected to a lesser extent [44, 45].

Although rats in the LPS group also displayed depressive-like behaviors, consistent with
previous reports [46, 47], we chose SD plus LPS as the model treatment. This was for two
reasons. First, based on clinical evidence, we used SD plus LPS to simulate the scenario seen
in humans [15, 48]. Second, in our study, the impact of SD plus LPS on the brain seemed
different to the synapse structure observed with SD or LPS alone. Compared with controls, no
significant changes were observed in the number of synapses, PSD thickness, or dendritic spine
density in the hippocampus of the LPS group.

Interestingly, according to TEM and Golgi-Cox staining, there was a significant increase
in the density of hippocampal dendritic spines in the SD group compared with control and
model animals (**Fig. 5**). Previous human and animal studies have demonstrated that
wakefulness increases synaptic strength in the cerebral cortex, whereas sleep can reduce
cortical synapses to restore synaptic balance. Many dendritic branches show a net reduction in
spines after sleep, with the remaining synapses generally being smaller [49, 50]. This
phenomenon is known as the synaptic homeostasis hypothesis [51, 52], and it effectively
explains the changes in synaptic function and structure observed in the SD group. Another
interesting hint is that the combination of SD and inflammation, the "two hits", can lead to
structural and functional impairments in synapses in the hippocampus, consistent with clinical
findings [51, 53, 54]. This reduction may be related to sleep pressure [55] and inflammation.
First, chronic SD results in a net increase in synaptic strength to saturation, with a subsequent
sudden increase in systemic inflammation exerting a dual impact of extensive synaptic
transmission disruption and synaptic damage, ultimately leading to decreased synaptic
plasticity [51, 56]. This interesting possibility now requires further exploration.

Another key criterion for a valid depression model is that model animals can be rescued
by classical antidepressants. In our study, model rats demonstrated a positive response to

fluoxetine treatment. More importantly, following treatment, there were improvements in both
behavioral outcomes and neuroinflammation and synaptic plasticity. Fluoxetine significantly
downregulated neuroinflammatory marker proteins, while synapse-related proteins were
upregulated. Immunofluorescence analysis revealed that fluoxetine rescued alterations in
GFAP$^+$ and IBA-1$^+$ cells and reversed changes in synaptic microstructure and dendritic spine
morphology. A meta-analysis suggested that fluoxetine modulates the recovery of
neurotransmission and neuroinflammatory pathways in human depression [57]. Furthermore,
Alboni et al. reported that fluoxetine may also enhance neuroplasticity in depression [58].
These findings are consistent with our observations in fluoxetine rescue experiments. However,
the results of the rescue experiment indicated that fluoxetine treatment did not ameliorate
synaptic dysfunction in the PFC of the MOD rats. It was likely due to the more severe synaptic
dysfunction inflicted on the PFC by the combined LPS and SD treatment compared to the
hippocampus, which is mentioned above. A three-week fluoxetine treatment may not be
sufficient to alleviate synaptic dysfunction in the PFC, suggesting that a longer treatment
duration may be required. This necessitates further exploration in future studies.

If our model is an effective model of human disease, we would expect it to simulate
transcriptional level changes seen in the brains of patients with depression. We therefore
conducted TWAS analyses of profiles obtained from human brain tissues corroborating the
two-hit model of depression. Of 33 validated genes, 16 exhibited consistent directional changes
in expression, with five genes having negative Z-scores and 11 positive Z-scores in the TWAS
analysis. Subsequent investigation of these depression risk genes revealed that five (*TLR9*, *C4A*,
LGALS3, *C1QB*, and *GRN*) are implicated in the immune and inflammatory responses, while
three (*GRN*, *C1QB*, and *CTTNBP2*) are involved in synaptic pathways.

There is existing evidence to support the involvement of *TLR9* and *C4A* in the pathogenesis
of depression. *TLR9*, a member of the toll-like receptor (TLR) family, activates
proinflammatory cytokine production. Pre-clinical and clinical studies have demonstrated that
TLR expression and TLR signaling regulators are associated with depression [59]. Additionally,
TLR also plays a role in innate immunity as measured in the postmortem brains of patients
with depression and suicide [60]. Dysregulation of *C4A* expression or activity has been
implicated in the perpetuation of neuroinflammation, with genetic studies associating *C4A*
polymorphisms with an increased susceptibility to depression [61, 62]. Future studies could
explore their potential as diagnostic biomarkers and therapeutic targets in depression.
CTTNBP2 plays a crucial role in regulating dendritic spine formation, modulating synaptic
signaling through its effects on the protein phosphatase 2A (PP2A) complex, potentially
affecting the specificity and efficiency of synaptic transmission [63]. It also regulates AMPA
receptor activity by influencing the trafficking machinery, thereby impacting synaptic strength
and plasticity [64]. The validation of these genes in human genetics studies further supports the
two-hit model and reinforces the fundamental role of neuroinflammation and synaptic
dysfunction in depression.

This study has several limitations. First, depression is a complex disease with potentially
multiple etiologies, and this model may not fully simulate all of these etiologies. This model
might need to be integrated with other existing models to provide further insights into
depression. Second, in our analysis, we selected two representative brain regions for analysis,

the hippocampus and PFC, but depression may affect other brain areas. Future studies could apply advanced techniques such as single-cell sequencing, spatial transcriptomics, and neural circuit techniques across the brain to further explore the model. Third, the transcriptomic analysis yielded other potentially important pathways, such as mitochondrial respiratory chain and learning and memory, but owing to space constraints, we focused on validating neuroinflammation and synaptic plasticity as they are among the most reproducible phenomena in clinical depression. However, this does not diminish the importance of other findings in the model group, which require further exploration. Lastly, the TWAS results need further validation, as TWAS power can be influenced by the quality of gene expression (sample sizes, coverage of eQTLs in the test dataset, *etc.*)

In conclusion, here we introduce a novel two-hit model of depression induced by SD and LPS that effectively replicates depressive-like behaviors in rodents. This novel rat model could be a valuable research tool for further investigation of the roles of insomnia and inflammation in the pathophysiology of depression.

Data availability

All data generated or analyzed during this study are either included in this published article or are available from the corresponding author upon reasonable request.

Acknowledgements

The authors are very grateful for the data support provided by the GTEx database and iPSYCH website. We gratefully acknowledge the contributions of Dr. Wei Wang, and Dr. Simeng Ma from Renmin Hospital of Wuhan University, as well as Dr. Zhiyu Luo from Wuhan First Hospital, to our work.

Author contributions

Junhua Mei: Writing - original draft, Project administration, Funding acquisition, Methodology. **Xinhua Song**: Methodology, Validation, Construction of the two-hit rodent model, Basic Experiment, Formal analysis, Writing - original draft, Visualization. **Ying Wang**: Methodology, Formal analysis, Writing - original draft, Visualization. **Honggang Lyu**: Methodology, Formal analysis, Writing - original draft, Visualization. **Guang Wang**, **Chao Chen**, and **Honghan Zhang**: Validation, Construction of the two-hit model. **Chao Wang**: Methodology, Writing - review and editing. **Xin-hui Xie**: Conceptualization, Methodology, Formal analysis, Writing - review and editing, Supervision. **Guohua Chen** and **Zhongchun Liu**: Funding acquisition, Supervision.

Funding

This work was supported by grants from the National Natural Science Foundation of China [grant numbers: U21A20364], the National Key Research and Development Program of China [grant number: 2018YFC1314600] and the Second Medical Leading Talent in Hubei Province.

Competing interests

The authors declare no competing interests.

References

1. Proudman D, Greenberg P, Nellesen D. The growing burden of major depressive
disorders (MDD): implications for researchers and policy makers. vol. 39.
Springer2021, pp 619-625.

2. Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating
neuroimaging and genetics. *Neuropsychopharmacology* 2021; **46**(1)**:** 156-175.

3. Cui L, Li S, Wang S, Wu X, Liu Y, Yu W *et al.* Major depressive disorder: hypothesis,
mechanism, prevention and treatment. *Signal Transduct Target Ther* 2024; **9**(1)**:** 30.

4. Ballesio A. Inflammatory hypotheses of sleep disturbance - depression link: Update and
research agenda. *Brain Behav Immun Health* 2023; **31:** 100647.

5. Yin J, Gong R, Zhang M, Ding L, Shen T, Cai Y *et al.* Associations between sleep
disturbance, inflammatory markers and depressive symptoms: Mediation analyses in a
large NHANES community sample. *Prog Neuropsychopharmacol Biol Psychiatry*
2023; **126:** 110786.

6. Liu L, Yang X, Yang C, Tian Y, Li W, Xia L *et al.* Associations between insomnia
symptoms and inflammatory cytokines in adolescents with first-episode and recurrent
major depressive disorder. *J Affect Disord* 2024; **350:** 110-117.

7. Plante DT. The Evolving Nexus of Sleep and Depression. *Am J Psychiatry* 2021;
178(10)**:** 896-902.

8. Khurshid KA. Comorbid Insomnia and Psychiatric Disorders: An Update. *Innov Clin*
Neurosci 2018; **15**(3-4)**:** 28-32.

9. Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and
Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and
Experimental Sleep Deprivation. *Biol Psychiatry* 2016; **80**(1)**:** 40-52.

10. Garbarino S, Lanteri P, Bragazzi NL, Magnavita N, Scoditti E. Role of sleep deprivation
in immune-related disease risk and outcomes. *Commun Biol* 2021; **4**(1)**:** 1304.

11. Piber D, Cho JH, Lee O, Lamkin DM, Olmstead R, Irwin MR. Sleep disturbance and
activation of cellular and transcriptional mechanisms of inflammation in older adults.
Brain Behav Immun 2022; **106:** 67-75.

12. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD.
Inflammatory markers in depression: A meta-analysis of mean differences and
variability in 5,166 patients and 5,083 controls. *Brain Behav Immun* 2020; **87:** 901-909.

13. Pitharouli MC, Hagenaars SP, Glanville KP, Coleman JRI, Hotopf M, Lewis CM *et al.*
Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic,
Health, and Psychosocial Factors: Results From the UK Biobank. *Am J Psychiatry* 2021;
178(6)**:** 522-529.

14. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum
interleukin 6 and C-reactive protein in childhood with depression and psychosis in
young adult life: a population-based longitudinal study. *JAMA Psychiatry* 2014; **71**(10)**:**
1121-1128.

15. Cho H, Eisenberger N, Olmstead R, Breen E, Irwin M. Preexisting mild sleep
disturbance as a vulnerability factor for inflammation-induced depressed mood: a
human experimental study. *Translational psychiatry* 2016; **6**(3)**:** e750-e750.

16. Irwin MR, Piber D. Insomnia and inflammation: a two hit model of depression risk and

prevention. *World Psychiatry* 2018; **17**(3)**:** 359-361.

17. Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj BMC, Robrecht S, Krzykalla J *et al.* Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. *Nat Commun* 2021; **12**(1)**:** 5395.

18. Huang W, Xu T, Li K, He J. Multiobjective differential evolution enhanced with principle component analysis for constrained optimization. *Swarm and Evolutionary Computation* 2019; **50:** 100571.

19. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014; **15**(12)**:** 550.

20. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (Camb)* 2021; **2**(3)**:** 100141.

21. Sato N, Tamada Y, Yu G, Okuno Y. CBNplot: Bayesian network plots for enrichment analysis. *Bioinformatics* 2022; **38**(10)**:** 2959-2960.

22. Zhang X, Wei M, Fan J, Yan W, Zha X, Song H *et al.* Ischemia-induced upregulation of autophagy preludes dysfunctional lysosomal storage and associated synaptic impairments in neurons. *Autophagy* 2021; **17**(6)**:** 1519-1542.

23. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW *et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet* 2016; **48**(3)**:** 245-252.

24. Alves-dos-Santos L, de Souza Resende L, Chiavegatto S. Susceptibility and resilience to chronic social defeat stress in adolescent male mice: No correlation between social avoidance and sucrose preference. *Neurobiology of stress* 2020; **12:** 100221.

25. Mao Y, Xu Y, Yuan X. Validity of chronic restraint stress for modeling anhedonic-like behavior in rodents: a systematic review and meta-analysis. *J Int Med Res* 2022; **50**(2)**:** 3000605221075816.

26. Strekalova T, Liu Y, Kiselev D, Khairuddin S, Chiu JLY, Lam J *et al.* Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives. *Psychopharmacology (Berl)* 2022; **239**(3)**:** 663-693.

27. Anisman H, Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. *Neurosci Biobehav Rev* 2005; **29**(4-5)**:** 525-546.

28. Becker M, Pinhasov A, Ornoy A. Animal models of depression: what can they teach us about the human disease? *Diagnostics* 2021; **11**(1)**:** 123.

29. Beurel E, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. *Neuron* 2020; **107**(2)**:** 234-256.

30. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. *Mol Psychiatry* 2023; **28**(1)**:** 284-297.

31. Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. *Brain Behav Immun* 2019; **81:** 24-40.

32. Xie XH, Lai WT, Xu SX, Di Forti M, Zhang JY, Chen MM *et al.* Hyper-inflammation of astrocytes in patients of major depressive disorder: Evidence from serum astrocyte-derived extracellular vesicles. *Brain Behav Immun* 2023; **109:** 51-62.

33. Xu Sx, Xie Xh, Yao L, Wang W, Zhang H, Chen Mm *et al.* Human in vivo evidence of reduced astrocyte activation and neuroinflammation in patients with treatment-resistant

depression following electroconvulsive therapy. *Psychiatry Clin Neurosci* 2023; **77**(12): 653-664.

34. Durkee C, Kofuji P, Navarrete M, Araque A. Astrocyte and neuron cooperation in long-term depression. *Trends Neurosci* 2021; **44**(10): 837-848.

35. Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X *et al.* Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. *Mol Psychiatry* 2016; **21**(10): 1358-1365.

36. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. *Brain Behav Immun* 2014; **42**: 50-59.

37. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. *Nat Med* 2016; **22**(3): 238-249.

38. R Vose L, K Stanton P. Synaptic plasticity, metaplasticity and depression. *Curr Neuropharmacol* 2017; **15**(1): 71-86.

39. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P *et al.* Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. *Nat Med* 2012; **18**(9): 1413-1417.

40. Castrén E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. *Biol Psychiatry* 2021; **90**(2): 128-136.

41. Correia AS, Cardoso A, Vale N. Oxidative Stress in Depression: The Link with the Stress Response, Neuroinflammation, Serotonin, Neurogenesis and Synaptic Plasticity. *Antioxidants (Basel)* 2023; **12**(2): 470.

42. Appelbaum LG, Shenasa MA, Stolz L, Daskalakis Z. Synaptic plasticity and mental health: methods, challenges and opportunities. *Neuropsychopharmacology* 2023; **48**(1): 113-120.

43. Marsden WN. Synaptic plasticity in depression: molecular, cellular and functional correlates. *Prog Neuropsychopharmacol Biol Psychiatry* 2013; **43**: 168-184.

44. Krause AJ, Simon EB, Mander BA, Greer SM, Saletin JM, Goldstein-Piekarski AN *et al.* The sleep-deprived human brain. *Nat Rev Neurosci* 2017; **18**(7): 404-418.

45. Salehinejad MA, Ghanavati E, Reinders J, Hengstler JG, Kuo MF, Nitsche MA. Sleep-dependent upscaled excitability, saturated neuroplasticity, and modulated cognition in the human brain. *Elife* 2022; **11**: e69308.

46. Novakovic MM, Korshunov KS, Grant RA, Martin ME, Valencia HA, Budinger GRS *et al.* Astrocyte reactivity and inflammation-induced depression-like behaviors are regulated by Orai1 calcium channels. *Nat Commun* 2023; **14**(1): 5500.

47. Zheng ZH, Tu JL, Li XH, Hua Q, Liu WZ, Liu Y *et al.* Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. *Brain Behav Immun* 2021; **91**: 505-518.

48. Vargas I, Perlis ML. Insomnia and depression: clinical associations and possible mechanistic links. *Curr Opin Psychol* 2020; **34**: 95-99.

49. De Vivo L, Bellesi M, Marshall W, Bushong EA, Ellisman MH, Tononi G *et al.* Ultrastructural evidence for synaptic scaling across the wake/sleep cycle. *Science* 2017; **355**(6324): 507-510.

50. Maret S, Faraguna U, Nelson AB, Cirelli C, Tononi G. Sleep and waking modulate spine turnover in the adolescent mouse cortex. *Nat Neurosci* 2011; **14**(11): 1418-1420.

51. Kuhn M, Wolf E, Maier JG, Mainberger F, Feige B, Schmid H *et al.* Sleep recalibrates homeostatic and associative synaptic plasticity in the human cortex. *Nat Commun* 2016; **7**(1): 12455.

52. Tononi G, Cirelli C. Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. *Neuron* 2014; **81**(1): 12-34.

53. Li B, Yang W, Ge T, Wang Y, Cui R. Stress induced microglial activation contributes to depression. *Pharmacol Res* 2022; **179**: 106145.

54. Park J, Chung WS. Astrocyte-dependent circuit remodeling by synapse phagocytosis. *Curr Opin Neurobiol* 2023; **81**: 102732.

55. Suppermpool A, Lyons DG, Broom E, Rihel J. Sleep pressure modulates single-neuron synapse number in zebrafish. *Nature* 2024; **629**(8012): 639-645.

56. Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. *Trends Neurosci* 2015; **38**(10): 637-658.

57. Almeida IB, Gomes IA, Shanmugam S, de Moura TR, Magalhaes LS, de Aquino LAG *et al.* Inflammatory modulation of fluoxetine use in patients with depression: A systematic review and meta-analysis. *Cytokine* 2020; **131**: 155100.

58. Alboni S, Van Dijk RM, Poggini S, Milior G, Perrotta M, Drenth T *et al.* Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. *Mol Psychiatry* 2017; **22**(4): 552-561.

59. Figueroa-Hall LK, Paulus MP, Savitz J. Toll-Like Receptor Signaling in Depression. *Psychoneuroendocrinology* 2020; **121**: 104843.

60. Pandey GN, Rizavi HS, Bhaumik R, Ren X. Innate immunity in the postmortem brain of depressed and suicide subjects: Role of Toll-like receptors. *Brain Behav Immun* 2019; **75**: 101-111.

61. Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY *et al.* Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. *Cell* 2016; **165**(4): 921-935.

62. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N *et al.* Schizophrenia risk from complex variation of complement component 4. *Nature* 2016; **530**(7589): 177-183.

63. Shih PY, Fang YL, Shankar S, Lee SP, Hu HT, Chen H *et al.* Phase separation and zinc-induced transition modulate synaptic distribution and association of autism-linked CTTNBP2 and SHANK3. *Nat Commun* 2022; **13**(1): 2664.

64. Anggono V, Huganir RL. Regulation of AMPA receptor trafficking and synaptic plasticity. *Curr Opin Neurobiol* 2012; **22**(3): 461-469.

 FIGURE LEGENDS

Fig. 1 Experimental paradigm and behavioral test outcomes in SD- and LPS-treated rats. Schematics of the model (A) and rescue experiment (D) design. Source consumption preference in the SPT (n = 12) (B, E). Immobility times in the FST (n = 12) (C, F). Data are expressed as mean ± SD. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$ by one-way ANOVA with Fisher's LSD multiple-comparisons test.

Fig. 2 Gene expression heatmaps and dotplots of enrichment analysis. Cluster analysis was conducted on the gene expression matrix from the hippocampus (A) and PFC (B). Enrichment analysis was performed for each cluster, and boxplots and heatmaps were generated to display the expression levels of each group. The GSEA results of the experimental groups from the hippocampus (C) and PFC (D) demonstrate differences in enriched pathways between groups.

Fig. 3 Enrichment analysis using the DEGs and Bayesian networks inferred from gene expression data in the hippocampus and PFC of the MOD group. (A and B) Results of the upregulated DEGs in the hippocampal MOD group, including Biological Processes (BP), Molecular Functions (MF), and Cellular Components (CC), and visualization of the interactions between these pathways. (C and D) Results of downregulated DEGs in the hippocampal MOD group. (E and F) Results of the upregulated DEGs in the PFC MOD group. (G and H) Results of the downregulated DEGs in the PFC MOD group.

Fig. 4 SD plus LPS treatment induces neuroinflammation in both the hippocampus and PFC. Western blotting analysis showing an increase of NLRP3 and ASC in MOD hippocampus (A) and PFC (D). Quantification of the NLRP3/GAPDH and ASC/GAPDH ratios (n = 6) in hippocampus (B, C) and PFC tissue (E, F). Representative immunofluorescence images of GFAP$^+$ and IBA-1$^+$ cells in CA1 (G), CA3 (J), DG (M), and PFC (P) in the indicated groups. Scale bars, 100 μm (white). Quantitation of GFAP$^+$ cell relative fluorescence intensity in the indicated groups (H, K, N, Q). Quantitation of the IBA-1$^+$ cell relative fluorescence intensity in the indicated groups (I, L, O, R). Data are expressed as mean ± SD. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$ by one-way ANOVA with Fisher's LSD multiple-comparisons test.

Fig. 5 SD plus LPS treatment induces synapse dysfunction in both the hippocampus and PFC. Western blotting analysis showing reductions in PSD95, SYN-1, SYP, and BDNF in MOD hippocampus (A) and PFC (F). Quantification of the PSD95/GAPDH, SYN-1/GAPDH, SYP/GAPDH, and BDNF/GAPDH ratios (n = 6) in hippocampus (B-E) and PFC (G-J) tissue. Representative TEM images of synapses of hippocampal neurons in the indicated groups. Scale bars, 1 μm (black) (K). Quantitation of synapse density (n = 9) (L). PSD thickness (M), PSD length (N), and RRP size (O) in neurons were evaluated in the indicated groups (CON, n = 17; LPS, n = 30; SD, n = 26; MOD, n = 18). Representative Golgi-Cox staining of dendritic spines in CA1 (P), CA3 (Q), and DG (R) in the indicated groups. Scale bars, 5 μm (red). Quantitation of dendritic spine density in different hippocampal regions as mentioned above (n = 9) (S-U). Data are expressed as mean ± SD. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$ by one-way ANOVA with Fisher's LSD multiple-comparisons test.

Fig. 6 Manhattan-style Z-score plot illustrating validated gene associations with depression in the TWAS analysis. TWAS results confirm the differential gene expression model. Sixteen validated genes from TWAS results across 13 brain tissues based on depression GWAS are represented as red dots. The red dashed lines indicate the TWAS significance threshold following Benjamini and Hochberg correction (*FDR.p* < 0.05). Genes positioned in the upper portion of the plot indicate that increased expression correlates with increased depression risk, while genes in the lower portion demonstrate an inverse association, consistent with the direction of the differential gene expression model.